MTI-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells

被引:53
作者
Sodek, K. L.
Ringuette, M. J.
Brown, T. J.
机构
[1] Samuel Lunenfeld Res Inst, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S 3G5, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
MTI-MMP; ovarian cancer; invasion; motility; collagen I; E-cadherin;
D O I
10.1038/sj.bjc.6603863
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Membrane- type 1 matrix metalloproteinase ( MTI- MMP), a transmembrane metalloprotease that plays an important role in the invasion of many solid tumour types, promotes pericellular matrix degradation and may also stimulate tumour cell motility. As both these processes are key contributors to intraperitoneal ovarian tumour metastasis, we examined six ovarian cancer cell lines to determine whether MTI is a critical mediator of invasive behaviour for this tumour type. Our results indicated that only those cell lines that expressed MTI were capable of penetrating a type I collagen barrier, with the capacity for both matrix degradation and invasion reflecting endogenous MTIexpression level. Ectopic MTI expression endowed an invasive phenotype upon cell lines lacking MTI that were previously non- invasive, indicating the crucial role of this protease. Conversely, invasion was abolished by tissue inhibitor of metalloproteinase- 2 ( TIMP- 2), a potent inhibitor of MTI, yet was minimally affected when other ( secreted) MMPs were inhibited using TIMP-I and the gelatinase inhibitor SB- 3CT. Whereas collagen I degradation was strikingly accelerated by ectopic MTI expression, cell motility remained unchanged. We conclude that MTI is necessary for collagen I invasion by ovarian cancer cells, and that its requisite activity is the promotion of matrix degradation, with no impact on cell motility.
引用
收藏
页码:358 / 367
页数:10
相关论文
共 69 条
[21]   Cell migration in 3D matrix [J].
Even-Ram, S ;
Yamada, KM .
CURRENT OPINION IN CELL BIOLOGY, 2005, 17 (05) :524-532
[22]   Recent advances in MMP inhibitor design [J].
Fisher, JF ;
Mobashery, S .
CANCER AND METASTASIS REVIEWS, 2006, 25 (01) :115-136
[23]  
Ghosh Supurna, 2002, Cancer Treat Res, V107, P331
[24]  
Giannelli G, 2001, CLIN EXP METASTAS, V18, P439
[25]   Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP) [J].
Gingras, D ;
Bousquet-Gagnon, N ;
Langlois, S ;
Lachambre, MP ;
Annabi, B ;
Béliveau, R .
FEBS LETTERS, 2001, 507 (02) :231-236
[26]  
Hashimoto K, 2005, CANCER RES, V65, P540
[27]   Cadherin switch in tumor progression [J].
Hazan, RB ;
Qiao, R ;
Keren, R ;
Badano, I ;
Suyama, K .
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 :155-163
[28]   Development of matrix metalloproteinase inhibitors in cancer therapy [J].
Hidalgo, M ;
Eckhardt, SG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03) :178-193
[29]   A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinurn containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study [J].
Hirte, H. ;
Vergote, I. B. ;
Jeffrey, J. R. ;
Grimshaw, R. N. ;
Coppieters, S. ;
Schwartz, B. ;
Tu, D. ;
Sadura, A. ;
Brundage, M. ;
Seymour, L. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :300-308
[30]   β-catenin activates a coordinated expression of the proinvasive factors laminin-5 γ2 chain and MT1-MMP in colorectal carcinomas [J].
Hlubek, F ;
Spaderna, S ;
Jung, A ;
Kirchner, T ;
Brabletz, T .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (02) :321-326